LY3202626

DRUG3 trials

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy Volunteers

Phase 1

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease

CompletedNCT02323334

Eli Lilly and CompanyAlzheimer Disease, Healthy Volunteers

Start: 2014-12-31End: 2016-02-29Updated: 2021-04-19

Phase 2

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

TerminatedNCT02791191

Eli Lilly and CompanyAlzheimer's Disease

Start: 2016-06-16End: 2018-07-02Updated: 2021-04-19

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

CompletedNCT03367403

Eli Lilly and CompanyAlzheimer Disease

Start: 2017-12-18End: 2021-09-21Updated: 2026-03-19

Alzheimer s & Dementia2025-12-01

Donanemab physiologically based pharmacokinetic model coupled with natural life cycle model for amyloid plaque aggregation to predict target CSF and ISF concentrations associated with amyloid plaque reduction

Alzheimer s & Dementia2025-12-01

Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab

Alzheimer s & Dementia2025-12-01

Regional tau quantification methodologies in early symptomatic participants with presence of tau pathology

Alzheimer s & Dementia2025-12-01

Donanemab exposure‐response in early symptomatic Alzheimer's disease

Alzheimer s & Dementia2025-07-015 citations

Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2025-07-011 citations

The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.

2025-07-01

JAMA Neurology2025-03-1059 citations

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.

2024-09-182 citations

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer s & Dementia2023-12-014 citations

Bayesian network analysis of BIN1 risk allele and other risk factors and biomarkers of Alzheimer’s disease

Alzheimer s & Dementia2023-12-011 citations

To Assess Mediation Effects of BIN1 Risk Variant rs6733839 and APOE4 on Alzheimer’s disease Pathology

Alzheimer s & Dementia2023-12-011 citations

Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

Alzheimer s & Dementia Translational Research & Clinical Interventions2023-07-0116 citations

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer s & Dementia2023-06-011 citations

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical Pharmacology & Therapeutics2023-02-1861 citations

Data‐Driven Methods Highlight Early Signals of Tau in Patients Lacking Global Uptake: Facilitating Enrollment in Clinical Trials

Alzheimer s & Dementia2022-12-01

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

JAMA Neurology2022-10-17229 citations

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes

JAMA Neurology2022-09-12172 citations

Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease

Alzheimer s & Dementia2021-12-013 citations

Donanemab in Early Alzheimer’s Disease

New England Journal of Medicine2021-03-131530 citations

6 more papers not shown

LY3202626

Sponsors

Conditions

Phase 1

Phase 2

Related Papers